Design for manufacture of an innovative Extra Corporeal Membrane Oxygenator

呼吸系统疾病每年花费NHS超过25亿英镑。该项目旨在提供安全有效的体外膜氧合，降低血凝块的风险，从而改善生活并降低这些成本。目前的替代品有引起血栓的倾向，因此需要高水平的抗凝。这种抗凝剂引入了出血的风险，在血栓形成和出血之间取得平衡，限制了少量昂贵的专科中心的使用。最初的重点是对心肺病人的术后支持，以提高康复率和减少住院时间。未来的发展可以预见，它将广泛应用于各种情况，包括对侵袭性流感大流行的无药物治疗，以及从长远来看，为患有慢性肺病的人提供支持。预计南威尔士工厂90%以上的产品将出口。

Respiratory problems cost the NHS over £2,500 million/annum. The project aims to deliver safe effective Extracorporeal Membrane Oxygenation with reduced risk of blood clots that will improve lives and reduce these costs. Current alternatives have a propensity to cause blood clots and consequently require high levels of anticoagulation. This anticoagulation introduces a risk of haemorrhage and striking a balance between thrombosis and haemorrhage restricts use to a small number of expensive specialist centres. The initial focus is on post-operative support for cardiopulmonary patients to improve recovery rates and reduce hospital stays. Future developments foresee application to a wide range of conditions including drug-free treatment for aggressive ‘flu pandemics and, in the longer term, support for people suffering chronic lung diseases. It is anticipated that over 90% of production from facilities in South Wales will be exported.